Ted Schenberg, Chief Executive Officer
Mr. Schenberg is a principal and co-founder of Caravel Ventures, a private equity group syndicating growth capital raises for lower middle market companies needing both financial and managerial support. Caravel’s current portfolio includes Strand Diagnostics (an FBI and CLIA-accredited forensic and medical DNA testing lab) for which Mr. Schenberg has been the CEO since 2007, and Animated Dynamics (engaged in the biodynamic imaging of cancer tissues) for which Mr. Schenberg is also CEO.
Mr. Schenberg has founded and/or acquired several companies in the life-science, chemical, aerospace, construction, internet security, construction, and food processing industries. He has an extensive track-record of executive leadership as well as building value for stakeholders in his companies in partnership with his management teams. He has deep experience with start-ups, turnarounds, and merger/acquisition activities with a strong emphasis on commercialization activities. Three of the companies founded or purchased by Mr. Schenberg were subsequently sold to publicly-traded firms. He holds two patents and has taught courses on business and entrepreneurship at assorted venues including Indiana University Kelly School of Business from which he also holds a BS in Accounting and a Masters in Business Administration.
Travis Morgan, Chief Financial Officer
After three years in the audit department of KPMG Peat Marwick focusing on lower middle market clients, Travis Morgan embarked on a successful career as a private equity investor and entrepreneur. As Co-founder and Managing Director of Caravel Ventures, Travis has been directly responsible for 18 capital infusions into 12 different operating companies, serving as the full-time President or CFO of 7 of those portfolio companies. His credits include securing over $103 million in funded capital transactions, including three liquidity events with publicly traded firms. Mr. Morgan graduated at the age of 20 from the Indiana University Kelly School of Business with a Bachelor of Science in Accounting and Finance, and is a CPA (inactive) licensed in Indiana. He received an MBA with concentrations in entrepreneurship and international business from Babson. He is a certified Lean Six Sigma Greenbelt, and an alumnus of the Indianapolis Business Journal’s “Forty under 40” list, recognizing the state’s top business leaders under the age of forty (class of 2000).
David Loesch, M.D., Chief Medical Officer
Dr. Loesch was a practicing medical oncologist with Central Indiana Cancer Centers for over 18 years before joining Caris Life Sciences. In addition to his clinical practice with CICC, he was the primary investigator and scientific director of the Indiana Cancer Research Foundation, a non-profit organization chartered by the hematologists and oncologists of Central Indiana Cancer Centers.
Dr. Loesch has made significant contributions in the area of breast cancer research and has served as co-chairman of the Breast Cancer Committees for the US Oncology (USO) Network and the Hoosier Oncology Group. In 2006, he was bestowed the Indiana Breast Cancer Alliance Medical Researcher Excellence Award, and in 2007 was named the Indiana Breast Cancer Researcher of the Year by the Indiana Breast cancer Coalition.
Dr. Loesch’s research on chemotherapy in breast cancer and in hormone refractory prostate cancer has been published extensively. In addition, the San Antonio Breast Cancer Symposium (SABCS) and the American Society of Clinical Oncology (ASCO) have accepted many of his abstracts. He is currently a member of ASCO and the American College of Physicians (ACP). He is a diplomate in both internal medicine and medical oncology.
Education and Professional Credentials:
- BS , Math, Institute of Technology, University of Minnesota, Minneapolis, MN
- D , University of Minnesota School of Medicine, Minneapolis, MN
- Internship, West Virginia University School of Medicine, Morgantown, WV
- Resident, University of Iowa Affiliate Program at Methodist Medical Center and Des Moines Veteran’s Administration Hospital, Des Moines, IA
- Fellow, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston, TX
Fellow, Medical Oncology, University of Texas at San Antonio, San Antonio, TX
Ran An, PhD, Chief Technical Officer and Co-founder
Dr. An has worked on the BioDynamic Imaging project for 7 years, including completion of his PhD thesis on the technology while studying under Dr. Nolte. He is the world expert on the technical details of the biodynamic imaging system. In 2013, Ran won Purdue’s Burton Morgan Business Plan Competition.
David D. Nolte, PhD, Chief Scientific Officer and Co-founder
Dr. Nolte is a professor of Physics at Purdue University with degrees from Cornell and UC Berkeley and is a serial entrepreneur with 7 years of experience in biotech start-ups. He was a co-founder of Quadraspec (now Perfinity), where he served as interim Chief Technical Officer and successfully brought their BioCD product to market. David is the holder of 17 issued US patents, including the first biodynamic imaging patent issued in 2014, and currently has six additional patents pending.
John J. Turek, PhD, Vice President and Co-founder
Dr. Turek is a professor of Basic Medical Sciences at Purdue University. He received his degrees in biology from the University of Illinois, Urbana, IL. He has extensive experience in multidisciplinary research and served as the founding Director of the Medical Discovery Resource Unit and is a Co-Director of the Preclinical and Translational Research Team for Indiana.
Wendy Blosser, Advisor
Ms. Blosser joined Animated Dynamics in April of 2018. She brings 20 years of great success in launching, relaunching and leading commercial organizations in diagnostic, surgical and capital sales. She also comes with extensive experience in marketing, corporate advocacy and sales training. Most recently, Wendy served as the Chief Commercial Officer for Biodesix, an oncology diagnostics company promoting blood based genomic and proteomic testing to Medical Oncologists, Thoracic Surgeons and Pulmonologists to assist in referral and treatment planning. In her time at Biodesix Wendy relaunched VeriStrat and brought the GeneStrat test to market. In that time the company showed continuous record growth of both products.
Prior to joining Biodesix, she served as Vice President of Sales with Integrated Oncology, responsible for leading the esoteric oncology laboratory business for this subsidiary of Laboratory Corporation of America. In that role Wendy’s responsibilities included business development activities in the area of qualifying acquisitions. She successfully integrated 2 of the largest oncology diagnostic firms (US Labs and Genzyme Genetics) under one umbrella and rebranded as Integrated Oncology. Along with this significant organizational restructuring came responsibility of consolidating, opening and closing various laboratory throughout the US. In her time with the company Integrated Oncology grew to be the largest oncology esoteric testing company worldwide.
Pervious to Integrated Oncology Wendy held national sales roles with Precision Therapeutics (now Helomics) and Vermillion. Wendy was brought on to Precision to relaunch the company’s struggling ChemoFx product. In her tenure with Precision Therapeutics revenue grew from $2.3M to over $23M within two years, and the year following nearly doubled revenue to $42mm. In addition to her relaunch experience of ChemoFx, Wendy has extensive start up experience with Vermillion and Cytyc Corporation. (Now Hologic).
Her time with Vermillion included product launch of OVA1, sales and marketing buildout, as well as society and government advocacy. Wendy held many roles in her time with Cytyc Corporation (now Hologic). Two key roles included: Director of Corporate Advocacy- In this role she effectively advocated and positioned Cytyc’s suite of products to national teaching institutions, the NIH, professional medical societies and government agencies. Product lines included The ThinPrep Pap Test and Imaging System, MammoSite Radiation Therapy System, NovaSure Endometrial Ablation System, and FullTerm product line. Wendy also held the role of Regional Business Director. In this position she was responsible for the financial results of the surgical and diagnostic mid-west division.
Ms. Blosser holds an M.S. from West Virginia University and a B.S. from Marietta College.